Pourrat Alix, Baillieu Vinciane, Ansel Solene, Leonardi Maxime, Poiron Pierre, Bellais Samuel, Paul Muriel, Nebbad Biba
Pharmacie à Usage Intérieur, Hôpitaux Universitaires Henri Mondor, Créteil, France.
BIOASTER, Lyon, France.
Front Microbiol. 2025 Aug 13;16:1618067. doi: 10.3389/fmicb.2025.1618067. eCollection 2025.
Fecal microbiota transplantation (FMT) is an effective treatment for recurrent infections. Freeze-drying offers a next-generation, more practical, and aesthetically acceptable FMT formulation that could facilitate standardized preparation methods. Viable preservation is a critical step in freeze-drying, yet no universal medium effectively protects both anaerobes and aerobes.
This study aimed to evaluate different protectants compared to trehalose 5% (T5) after confirming its efficacy.
A mix of inulin and glucosamine (IG5) and a High-antioxidant Matrix with trehalose (HM) were tested. Viability was assessed using colony-forming unit (CFU) enumeration and flow cytometry with a LIVE/DEAD™ staining method.
T5 demonstrated satisfactory bacterial recovery after freeze-drying, with viability of 84 ± 28% for anaerobes and 59 ± 39% for (BIF), confirming its efficiency in our preparation facilities. While HM showed highest results (91 ± 7% for anaerobes, 121 ± 33% for BIF), it did not significantly outperform T5. IG5, however, resulted in a significant loss of bacteria, with only 16 ± 12% viability for anaerobes ( = 0.016) and 19 ± 9% for BIF ( = 0.031).
HM and T5 both proved effective for freeze-dried FMT, with HM yielding the highest recovery but not significantly outperforming T5. Given its simplicity and consistent results, T5 may serve as a reliable standalone protectant or as a base for improved formulations. IG5 showed significant bacterial loss and is unsuitable. Further biological validation and stability data will guide the development of optimized freeze-dried oral FMT capsules.
粪便微生物群移植(FMT)是治疗复发性感染的有效方法。冷冻干燥提供了一种新一代、更实用且美观上可接受的FMT制剂,可促进标准化制备方法。活菌保存是冷冻干燥的关键步骤,但尚无通用培养基能有效保护厌氧菌和好氧菌。
本研究旨在在确认5%海藻糖(T5)有效性后,评估与之相比的不同保护剂。
测试了菊粉和氨基葡萄糖混合物(IG5)以及含海藻糖的高抗氧化基质(HM)。使用菌落形成单位(CFU)计数和采用LIVE/DEAD™染色法的流式细胞术评估存活率。
T5在冷冻干燥后显示出令人满意的细菌回收率,厌氧菌存活率为84±28%,双歧杆菌(BIF)为59±39%,证实了其在我们制备设施中的有效性。虽然HM显示出最高结果(厌氧菌为91±7%,BIF为121±33%),但并未显著优于T5。然而,IG5导致细菌显著损失,厌氧菌存活率仅为16±12%(P = 0.016),BIF为19±9%(P = 0.031)。
HM和T5均被证明对冷冻干燥的FMT有效,HM回收率最高,但未显著优于T5。鉴于其简单性和一致的结果,T5可作为可靠的独立保护剂或改进制剂的基础。IG5显示出显著的细菌损失,不适用。进一步的生物学验证和稳定性数据将指导优化的冷冻干燥口服FMT胶囊的开发。